BACKGROUND & AIMS:
Gene expression profiling provides an opportunity for definitive diagnosis, but has not yet been well applied to inflammatory diseases. Here we describe an approach for diagnosis of an emerging form of esophagitis, eosinophilic esophagitis (EoE), which is currently diagnosed by histology and clinical symptoms. METHODS: We developed an EoE diagnostic panel (EDP) comprising a 96-gene quantitative polymerase chain reaction array and an associated dual-algorithm that uses cluster analysis and dimensionality reduction using a cohort of randomly selected esophageal biopsy samples from pediatric patients with EoE (n ¼ Q6 15) or without EoE (non-EoE controls, n ¼ 14) and subsequently vetted using a separate cohort of 194 pediatric and adult patient samples derived from both fresh or formalin-fixed, paraffin-embedded tissue: active EoE (n ¼ 91), control (non-EoE and EoE remission, n ¼ 57), histologically ambiguous (n ¼ 34), and reflux (n ¼ 12) samples. RESULTS: The EDP identified adult and pediatric patients with EoE with approximately 96% sensitivity and approximately 98% specificity, and distinguished patients with EoE in remission from controls, as well as identified patients exposed to swallowed glucorticoids. The EDP could be used with formalin-fixed, paraffin-embedded tissue RNA and distinguished patients with EoE from those with reflux esophagitis, identified by pH-impedance testing. Preliminary evidence showed that the EDP could identify patients likely to have disease relapse after treatment. CONCLUSIONS: We developed a molecular diagnostic test (referred to as the EDP) that identifies patients with esophagitis in a fast, objective, and mechanistic manner, offering an opportunity to improve diagnosis and treatment, and a platform approach for other inflammatory diseases.
Keywords: EoE; GERD; Nonerosive Reflux Disease; Diagnostic Panel; Signature; Eosinophil; EoE Transcriptome; Fluidic Card. E osinophilic esophagitis (EoE) is a recently identified chronic, immune-mediated, clinicopathological, upper gastrointestinal (GI) disorder. It is characterized by esophageal dysfunction (eg, dysphagia) and eosinophilia of !15 eosinophils/high-power field (HPF) in patients for whom acid-induced esophageal injury has been excluded. 1 The incidence of EoE has continued to increase since its initial characterization 2 decades ago, 2 and EoE now accounts for approximately 10%À30% of chronic esophagitis refractory to proton pump inhibitor therapy 1 and 7% of patients who undergo upper GI endoscopy. 3 The treatment of EoE is distinct from other forms of esophagitis, such as gastroesophageal reflux disease (GERD), as effective management depends on elimination of the triggering food or the use of anti-inflammatory medications (eg, glucocorticoids). Until now, the only widely accepted means of diagnosing EoE was based on this histological analysis of esophageal biopsies together with clinical symptom evaluation, 4 and it has been suggested that at least 5 biopsies, preferably from both the distal and proximal esophagus, are required to obtain sufficient sensitivity because of the patchiness of disease pathology. [5] [6] [7] Unfortunately, esophageal eosinophilia is not specific to EoE, as it also occurs in other disease processes, including GERD, infections, and autoimmune diseases, rendering specificity of histology-based diagnosis problematic. 8 One of the critical findings in understanding EoE pathogenesis was the discovery of the whole-genome messenger RNA esophageal expression profile (EoE transcriptome). 9 The EoE transcriptome consists of approximately 500 EoE genes and has uncovered key pathogenic steps, such as the involvement of eotaxin-3 in eosinophil accumulation and activation; the importance of periostin in facilitating eosinophil recruitment and tissue remodeling 10 ; the critical role of mast cells, 11 T cells, 12 and the local cytokine milieu 13 in disease pathogenesis; and the importance of impaired local barrier function.
14 Ideally, microarray expression can be used to provide diagnosis of EoE. 9 However, the long turnaround time, the technical complexity of the messenger RNA microarray, and the associated high financial cost hinder practical clinical application for diagnostic purpose.
To utilize the diagnostic strength from the microarray and reduce technical barriers, we developed a molecular EoE diagnostic panel (EDP) built on a TaqmanqPCRÀbased low-density array system. Here, we report 3 major steps in the development and application of the EDP. First, we successfully demonstrate that a selected representative EoE gene set (a 94-gene panel) is sufficient to provide EoE diagnosis with high sensitivity and specificity (92%À100%, 96%À100%, respectively), based on dualcomputational algorithms in both pediatric and adult EoE. Second, we demonstrate that EoE remission patients can be readily distinguished from normal (NL) patients, which cannot be achieved by conventional methods. Third, we demonstrate the utility of the EDP with formalin-fixed, paraffin-embedded (FFPE)Àderived tissue RNA and in distinguishing EoE from GERD, using pHimpedance testing to confirm the presence of acidinduced disease. Taken together, the EDP has promising future applications in the classification of esophagitis and in advancing personalized medicine.
Materials and Methods

Patient Sample Selection
For algorithm-developing cohorts, NL patients were defined by the distal esophagus (where tissue RNA was obtained) having 1 eosinophil/HPF and by not being treated with swallowed or systemic steroids without EoE history. Patients with EoE were selected for having !15 eosinophil/HPF in the distal esophagus, typically when on proton pump inhibitor therapy, and by not being treated with swallowed or systemic steroids. Patients with EoE remission were selected based on having partial ( 2 eosinophil/HPF) or complete ( 1 eosinophil/HPF) histological remission (mean 0.6 AE 0.7 eosinophil/HPF) after topical fluticasone propionate or budesonide treatment. The selection criterion was based on the peak eosinophil count in the distal esophageal biopsies, which is the only tissue type assayed in this report. All EoE patients tested were clinically symptomatic pediatric patients younger than 21 years old, with the exception of the adult transcriptome assay, which recruited 12 adults older than 22 years old. In a replication study and the overall study, control samples were defined as 2 eosinophil/HPF. For the collective FFPE diagnostic merit study and the impedanceguided study, NL was defined as 0 eosinophil/HPF with no history of EoE), and EoE was defined as !15 eosinophil/HPF on proton pump inhibitor therapy. For detailed clinical information, see Supplementary Table 3 .
RNA Extraction and Reverse Transcription
Biopsy messenger RNA/microRNA extraction was carried out routinely by miRNeasy RNA extraction kit (217004; Qiagen, Valencia, CA); samples were archived in the À80 C eosinophilicgastrointestinal disorder
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(EGID) research sample library at Cincinnati Children's Hospital Medical Center and registered in an electronic EGID database. An aliquot of RNA was reversetranscribed to complementary DNA by the iScript cDNA Synthesis Kit (170-8891; Bio-Rad, Hercules, CA). Briefly, 500 ng RNA was mixed with the reaction mixture containing reverse transcriptase and deoxynucleoside triphosphates in a total volume of 20 mL; incubated at 25 C for 5 min, 42 C for 30 min, 85 C for 5 min; and then kept at À20 C for storage.
Taqman qPCR Amplification With 384-Well Fluidic Cards
An aliquot of complementary DNA equivalent to 125À500 ng starting RNA was adjusted to 100 mL with H 2 O and mixed with 100 mL TaqMan Universal PCR Master Mix (4440040; Applied Biosystems, Carlsbad, CA) and loaded on fluidic cards. The standard amplification protocol consists of a ramp of 50 C for 2 minutes and a hot start of 94.5 C for 10 minutes, followed by 40 cycles of 30 seconds at 97 C and 1 minute at 59. 7 C.
Esophageal pH Impedance-Guided EDP
We systematically searched the hospital's (Cincinnati Children's Hospital Medical Center) pH-multichannel intraluminal impedance (MII) results for patients who had the pH-MII performed for upper GI symptoms and also had an esophageal biopsy report available concurrently (gap between the 2 procedures was a mean 2 AE 2 days, with 2 exceptions of 65 and 143 days). These 38 patients were divided into 4 different study cohorts based on their histological report and concurrent esophageal impedance, namely NL (normal pathology, normal impedance), nonerosive reflux disease (normal pathology, abnormal impedance), GERD (abnormal pathology [2À6 eosinophils/HPF inflammatory infiltration, and/or with neutrophilia, without EoE history], abnormal impedance), and EoE (abnormal pathology [!15 eosinophils/HPF], normal impedance). We defined an abnormal pH-MII result as having >80 reflux episodes in 24 hours, which is further defined as a retrograde decrease in impedance baseline that exceeded 50% of the distance between the baseline and the impedance nadir in at least the 2 distal channels. Similar criteria have recently been recognized. 15 
Results
Two Independent Algorithms, Cluster Analysis and EoE Score, Successfully Differentiate EoE From NL Patients
The Taqman amplification reagents for a panel of 94 representative EoE genes and 2 housekeeping genes were pre-embedded onto a 384-well fluidic card ( Table 1,  Supplementary Tables 1 and 2 ). CDH26  FLG  TNFAIP6  POSTN  CLC  CCL26  DSG1  UPK1A  ALOX15  KRT23  CCR3  CXCL1  CLDN10  SPINK7  ARG1  COL8A2  TPSB2/AB1  IL4  CTNNAL1  CRISP3  MMP12  CTSC  CPA3  IL5  CHL1  MUC4  IGJ  ACTG2  CMA1  IL13 schematic summary of the steps involved. For algorithm development, a random set of samples from pediatric patients including NL (n ¼ 14) and EoE (n ¼ 15) samples without exposure to topical or systemic glucocorticoid treatment were selected for initial EDP analysis (for clinical information see Supplementary Table 3 ). We identified 77 significantly dysregulated genes out of the 94 genes after false discovery rate correction 16 (false discovery rateÀcorrected P < .05 by 2-tailed t test, fold change >2.0). As shown in Figure 2A , we initially examined NL (blue branches) and EoE (red branches) samples with established histological diagnosis and then setup a 2-dimensional dendrogram, clustering on both entities (genes) and conditions (EoE status), based on a Pearsoncentered similarity algorithm. The clustering on the Y-axis demonstrated that the up-regulated and downregulated EoE genes were well represented by the EDP platform. Judging from the first branch of the dendrogram on the X-axis (condition), the EoE pattern can be readily recognized with a long-distance metrics separation on top of the dendrogram. All of the NL samples clustered together and all of the EoE samples grouped together ( Figure 2A ). Multidimensional scaling analysis of the 77 differentially expressed EoE genes established a 3-dimensional plot based on Euclid distance between samples ( Figure 2B ), which demonstrated a clear separation of EoE and NL samples.
We also developed a parallel dimensionality reduction algorithm to calculate an EoE score (see Methods), with the goal of developing a quantitative diagnostic cut-off. As shown in Figure 2C , the EoE score of the 2 cohorts was well separated with 100% disease prediction. Notably, the EoE score cut-off (333) was determined through a largerscale study consisting of 132 patients (discussed later Q8
). With the EoE score algorithm, receiver operating characteristic (ROC) analysis demonstrated an excellent diagnostic merit with area under curve (AUC) being 1.00 ( Figure 2D ). There was a significant correlation between the EoE score and esophageal eosinophil counts ( Figure 2E ; P < .0001), a surrogate marker of disease severity. Two mast cell markers, carboxypeptidase A3 and tryptase, correlated well with each other ( Figure 2F , left 
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Graphic illustration of EDP standard operating procedures. The EDP described in this report consists of 3 major steps, namely RNA extraction, EDP panel quantitative polymerase chain reaction (qPCR), and data analysis. RNA is extracted from a fresh patient esophageal biopsy or FFPE tissue sections. An aliquot of the RNA sample is subjected to reverse transcription reaction, and the resulting complementary DNA is loaded onto the 384-well fluidic card (4 patients) for qPCR amplification. The qPCR data are subjected to dual algorithms, namely signature analysis (heatmap clustering) and dimensionality reduction (EoE score) to establish molecular EoE diagnosis, which forms the basis for the final diagnostic report with multiple disease pathogenesis component assessment. Th2, type 2 helper T cells; SDCT, sum of normalized CT. 233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290   291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348 panel) indicating intra-panel reproducibility. Also, the gene for eosinophil lysophospholipase (CLC), the only highly expressed eosinophil granule protein gene, positively correlated with mast cell gene levels ( Figure 2F , middle panel) and eosinophil counts ( Figure 2F , right panel), corroborating earlier findings.
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In a replication study, we also performed EDP analysis on a biologically independent cohort of control (n ¼ 14) and EoE (n ¼ 18) patients (for clinical information, see Supplementary Table 3 ). The cluster analysis dendrogram predicted control (blue branch) vs EoE (red branch) with high accuracy (Supplementary Figure 1A) , and the EoE print & web 4C=FPO Figure 2 . Dual EDP algorithms for molecular diagnosis of EoE. (A) For the 94 EoE genes embedded, a statistical screening was performed between the 14 normal (NL) patients (blue branch) and 15 patients with EoE (red branch), resulting in 77 genes with false discovery rateÀcorrected P < .05 and fold change >2.0. Based on these 77 core genes, a heat map (red: up-regulated) was created, with the hierarchical tree (dendrogram) established on both gene entities and sample conditions. On the x-axis, the first branch of the top tree is utilized to predict EoE vs NL. (B) The 77-gene/dimension expression data on 14 NL controls (blue) and 15 patients with EoE (red) were reduced to 3-dimensional presentation by multidimensional scaling analysis for visual presentation of the expression distance between samples. (C) An EoE score was developed based on dimensionality reduction to distinguish EoE vs NL and quantify EoE disease severity. A diagnosis cut-off at EoE score ¼ 333 (dashed line) was derived from later, larger-scale studies by ROC analysis. Figure 1C) . Similarly, the EoE score strongly correlated with disease severity (Supplementary Figure 1D) , as measured by eosinophils/HPF (Supplementary Figure 1E) . 
EDP Indicates a Comparable EoE Transcriptome Between Adult and Pediatric Samples
We aimed to determine whether the EDP would be sufficient across age groups. Adult and pediatric patients with EoE (matched for eosinophil levels) were subjected to the EDP analysis (Supplementary Figures 3A and B) . Notably, the 77 core gene expression signatures were largely comparable between pediatric and adult patients with EoE by both clustering and EoE score analyses ( Supplementary Figures 3C and E) . Multidimensional scaling analysis indicated 2 distinct groups when pediatric NL (blue dots) and EoE (red dots) samples were analyzed, indicating a large Euclid distance (Supplementary Figure 3D, left panel) ; in contrast, pediatric EoE (red) and adult EoE (blue) samples exhibited a mixed pattern due to a similar signature (Supplementary Figure 3D , right panel).
EDP Identifies EoE Remission Status
The dysregulated expression of a subset of the EoE transcriptome is resistant to steroid therapy, even when steroid therapy induces remission, ie, the absence of tissue pathology including eosinophilia. 17 In addition, there is a unique set of genes that are up-regulated in response to glucocorticoid exposure. 18 Therefore, we included a selection of EoE remission genes, as well as several steroid-induced markers, in the EDP design, aiming to distinguish EoE remission and NL and to assess glucocorticoid exposure (for genes related to these purposes, see Supplementary Table 2) . EDP analysis of esophageal biopsies from patients with EoE responding well to swallowed topical fluticasone propionate (Flovent, green) therapy or budesonide (Pulmicort, light blue) identified 44 and 28 dysregulated genes, respectively, with an overlap of 22 genes between the 2 steroids ( Figure 3A) . Within this 22-gene set, we derived a scoring algorithm, EoE remission score, to quantitatively differentiate between NL and EoE remission. Judged by an ROC-derived cut-off of EoE remission score of 74, NL and the 2 EoE remission cohorts were well discriminated ( Figure 3B ). The rectangular-shaped ROC curve demonstrated high diagnostic merit ( Figure 3C) . Notably, the 77-gene EoE definitive diagnosis cluster on the same panel could not distinguish the remission cohorts from the NL cohort, which is conceivable, as these are inactive samples ( Figure 3D ).
EDP Analysis of Histologically Ambiguous Patients Identifies a Significant Subset of EDPPositive Patients Associated With Worse Prognosis
In clinical practice, when esophageal eosinophil numbers are less than the diagnostic threshold (eg, in the range of 6 to 14 eosinophils/HPF), a diagnostic dilemma is posed. In order to clarify potential EoE cases within this "subdiagnosis zone," 13 we utilized the EDP and the associated algorithms to assess the signature of this histologically ambiguous population in a cohort of 34 pediatric patients with eosinophil counts in the subdiagnosis zone (6À14 eosinophils/HPF). Juxtaposition of the expression signatures of the histologically ambiguous patients with NL and EoE reference cohorts ( Figure 4A ) demonstrated that the ambiguous cohort had a unique molecular signature with EoE up-regulated genes modestly increased but EoE down-regulated genes largely unchanged. When analyzed by the EoE score algorithm, 47% of these patients (16 of 34) had a positive EDP score ( Figure 4B ). After dimensionality reduction, we further positioned this ambiguous cohort (green, n ¼ 34) onto a 3-dimensional expression plot by multidimensional scaling ( Figure 4C ), demonstrating that the signature of these patients was distinguished from NL (blue) and EoE (red) reference cohorts with their Euclid distance closer to NL ( Figure 4D ). In order to study whether this initial signature change could be predictive for long-term prognosis of EoE, we examined the clinical outcomes of these 34 patients (with 6À14 eosinophils/ HPF) by tracking their medical records and found that 69% of the EDP-positive patients and 33% of the EDP-negative patients developed active EoE (!15 eosinophils/HPF) within 2 years (mean, 1.2 AE 0.5 years; range, 0.4À2 years; n ¼ 17). In Figure 4E , by c 2 test, there was a substantial risk for developing active EoE after a positive EDP (odds ratio ¼ 4.4; P ¼ .039). 465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522   523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578 579 580
FFPE Compatibility and a Ph ImpedanceBased Study for EoE vs GERD Differentiation by EDP Analysis
We next explored whether the EDP was able to analyze FFPE sections from EoE and NL samples defined by histological criteria in clinically symptomatic EoE patients. Cluster analysis of NL (n ¼ 21) and EoE (n ¼ 24) FFPE samples demonstrated a pronounced separation between the 2 groups (Supplementary Figure 4A) , resulting in a sensitivity of 96% and specificity of 100%. Likewise, the EoE score algorithm separated the same NL and EoE cohorts in the FFPE format with high merit (sensitivity 92%, specificity 100%). With an AUC of 0.96 from ROC analysis and an optimized cut-off of 355 (Supplementary Figure 4B) , the performance of the EDP of FFPE samples proved to be comparable with fresh samples. In addition, we wanted to assess the reproducibility between 2 different section cuts from the same FFPE block, which is a function of both histological and technological variations. The 2 FFPE RNA extractions and EDP amplifications were performed at least 1 month apart. The raw CT values were 2-dimensionally plotted (cut 1 vs cut 2) to reveal the correlation of the adjacent section inputs (8 Â 10 mm cut twice), which indicated a high reproducibility between different tissue inputs on the same archived tissue (Supplementary Figure 4C) . Finally, we evaluated the correlation between a FFPE biopsy and a fresh biopsy taken simultaneously from the same patient; notably, a high correlation for individual gene expression was observed (Supplementary Figure 4D) . Across larger cohorts, comparing the algorithm-developing cohort (fresh, n ¼ 29) and the FFPE cohorts (n ¼ 45), the dysregulation vectors (fold change EoE over NL; red indicating up-regulated genes; blue for down-regulated) robustly correlate between fresh and FFPE samples (r 2 ¼ 0.87, Supplementary Figure 4E) . Supplementary Figure 4F , left panel illustrates a representative 230À280 nm spectrometry result for RNA isolated from 80-mm FFPE sections with high RNA purity and microgram-level abundance. RNA integrity analysis by the Agilent 2100 , n ¼ 6) were acquired by EDP. Statistical analysis between the normal (NL) cohort and the 2 EoE remission cohorts was performed (false-discovery rateÀcorrected P < .05, fold change >2.0), which resulted in 22 significant genes present in both FP-and BUD-regulated gene sets. On the basis of this 22 remission genes, a double-clustered heat map was generated to evaluate the gene expression pattern of EoE remission (FP, green; BUD, light blue) compared with NL (blue) and EoE (red). (B) The EoE remission score for each patient was calculated by 1-dimensional reduction with the same formula for EoE score to differentiate the patients with EoE remission (R) (FP R and BUD R) from NL quantitatively. (C) A diagnostic cut-off line of EoE R score of 74 was derived from ROC analysis, which has an AUC of 1.00. (D) On the basis of the 77 EoE diagnostic genes, EoE scores were also calculated to assess the EoE status of these remission patients. The EoE score ¼ 333 cut-off line is indicated on the graph. All scatter plots were graphed as mean AE SEM.
Bioanalyzer revealed substantial FFPE RNA degradation as a function of time (Supplementary Figure 4F, right  panel) ; however, the EDP performance was unaffected, as the FFPE samples had a conserved signature pattern compared with fresh RNA, even though the RNA was 0À3 years old (Supplementary Figure 4A, B) . Collectively, these print & web 4C=FPO Figure 4 . EoE transcriptome pattern in the patient population with ambiguous eosinophil (EOS) levels, 6À14 EOS/HPF. (A) To acquire the esophageal signatures of 34 patients with noticeable eosinophilia that did not exceed the diagnostic cut-off (6 <EOS/HPF <15), EDP-based expression signatures were juxtaposed with the reference normal (NL, 0 EOS/HPF) and eosinophilic esophagitis (EoE, >15 EOS/HPF) cohorts. (B) The EoE score algorithm was utilized to assess EoE signature within the population with ambiguous EOS levels of 6À14 EOS/HPF (6À14/HPF). The EoE score scatter plot indicates that approximately 47% (16 of 34) patients in this subdiagnosis zone were EDP positive, as determined by the 333 EoE diagnostic cut-off (dashed line). (C) Multidimensional scaling analysis was carried out to visualize the expression difference between the 6À14 EOS cohort (green) and NL (blue), and EoE (red) reference cohorts. (D) The average (Avg) Euclid distances from the 6À14 EOS cohort to the NL and EoE cohorts, respectively, were graphed as mean AE 95% confidence interval, revealing their collective Euclid distance to NL and EoE reference cohorts, respectively. ***P < .001. (E) All 34 patients with ambiguous EOS levels (6À14 EOS/HPF) were clinically followed for 2 years based on their medical record. The association between EDP results and subsequent active EoE (>15 EOS/HPF) (in mean, 1.2 AE 0.5 years) was graphed in the c 2 table. The odds ratio of 4.4 was calculated based on the relative risk factor for EoE development, EDP-positive (EoE score <333) vs EDPnegative result, with a significant P value ¼ .039 by c 2 test. 697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754   755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812 data demonstrated that the dual-diagnostic algorithms derived from fresh samples readily applied to clinically archived FFPE samples and resulted in uncompromised diagnostic merit. In order to definitively prove the capacity of the EDP to differentiate EoE from GERD and to further validate the FFPE sample compatibility, we examined a cohort of 38 patients with upper GI symptoms who concurrently underwent both esophagogastroduodenoscopy
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and esophageal pH-MII analysis. The expression heat map was juxtaposed based on core EoE genes and patient grouping conditions with their reflux episodes within 24 hours displayed by overhead bars ( Figure 5 ). For pH-MII reading, we used >80 episodes cut-off to define reflux condition (see Methods for pH-MII definition and grouping criteria). The nonerosive reflux disease group was highly comparable with NL controls, likewise, the expression pattern of the pathological GERD cohort was molecularly similar to that of NL controls.
Overall EDP Analysis on a Larger Scale
We next aimed to evaluate the diagnostic merits of the EDP by examining the transcription signatures of 166 fresh RNA samples. Among the 166 patients, 132 had eosinophil counts in the ranges in which diagnosis was considered unambiguous (eg, 2 or !15 eosinophils/ HPF), forming the control and EoE pool, respectively (for clinical information see Supplementary Table 3 ). The clustering analysis indicated the distinct cohorts of EoE transcriptome and NL-like transcriptome ( Figure 6A ). Under the first branch, the uniformity of tree color reflects diagnostic merit. Using the EoE score algorithm ( Figure 6B ) and ROC cut-off optimization ( Figure 6C ), we demonstrated that the EDP had an excellent coverage between sensitivity (92%) and specificity (96%) and a high AUC of 0.97 ( Figure 6C and D) . In order to assess whether EoE score could reflect disease severity as measured by histology (eg, eosinophils/HPF) for these 166 cases, we performed nonparametric regression analysis with the predicted model shown in red dots and the true values shown in blue dots ( Figure 6E ). The r 2 of 0.68 is indicative of a strong correlation between the 1-dimensional EoE score and tissue eosinophilia, which is the currently accepted gold standard for measurement of disease activity.
Discussion
EoE is an emerging and enigmatic disease, whose diagnostic standards still remain debatable. In this report, we demonstrated a readily performed molecular platform providing differential diagnosis of EoE vs NL and inactive EoE, EoE vs nonerosive reflux disease/GERD, and EoE remission vs NL by dual-computational algorithms. The EDP panel was shown to be FFPE sample compatible with comparable merit to analysis of fresh tissue and applicable to pediatric and adult EoE. The EDP also demonstrated the predicative capacity for patients with subclinical histology, suggesting that these patients should be tightly monitored as an EoE high-risk population and that the EDP might potentially be used as a personal medicine prediction device. The EDP has the potential to overcome the limitations of histological analysis, as it provides potentially deeper insight into tissue processes that are not all visible microscopically or that can be microscopically patchy, highlighting the transformative value of using molecular parameters compared with histology for the diagnosis of inflammatory diseases. In addition, the EDP has the capacity to reveal EoE pathogenesis that could vary from patient to patient, forming the basis for practicing personal medicine. It is important to note that the EDP has a high performance using only 1 distal esophageal biopsy, even though consensus recommendations include procurement of 5 biopsies. 1 The EDP can readily differentiate topical steroid-induced EoE remission samples from NL samples by both algorithms-a capacity histology does not have, print & web 4C=FPO Figure 5 . A pH impedance-guided EDP analysis aiming to discriminate nonerosive reflux disease/GERD from EoE. The EDP was performed on a selected cohort of 38 patients who had pH-MII results from the time of endoscope procedure; they were categorized into 4 different cohorts based on pathology findings and pH-MII test. Expression heat map was generated based on 36 significant genes after a statistical screening between NL patients and patients with EoE (false-discovery rate-corrected P < .05, fold change >2.0). Four study cohorts, namely NL, nonerosive reflux disease (NERD), GERD, and EoE were juxtaposed for signature comparison. The overhead "Reflux episode" bars indicate the number of esophageal reflux episodes within 24 hours by pH-MII with a cut-off of 80 displayed. # 2À6 eosinophils (EOS)/HPF and/or with neutrophilia. EDP was performed on FFPE-derived RNA in this retrospective study.
and subjective steroid compliance can be objectively predicted with steroid-responding biomarkers. Besides the steroid intervention assessment, a future EDP study should also be performed in the context of diet retreatment. It would be interesting to prospectively evaluate the effects of multiple forms of diet therapy, such as elimination vs elementary, in reference to steroid effects. Importantly, it is proposed that, with a paired-sample study before and after EoE treatments, the EDP (in its current form or with modified composition) will predict which treatment is more effective (eg, reversing the EDP signature). This approach will be critically important for selection of the most effective intervention for EoE patients, which is currently not fully agreed on.
In clinical practice, physicians often face a diagnostic dilemma when patients with esophagitis have clinical symptoms comparable with EoE yet have endoscopic findings with <15 eosinophils/HPF. 19 The cut-off value of 15 eosinophils/HPF has been questioned recently, even in a recent Consensus Report. 1 Even within 1 biopsy, the eosinophil number varies from site to site. The EoE score algorithm indicated that 47% of the histologically ambiguous patients are molecularly equivalent to active EoE patients. Fifty percent of these histologically ambiguous patients later developed histologically active EoE within a 2-year period, indicating that these patients are at high risk for active EoE. A positive EDP coupled with subclinical nonremission histology (6À14 eosinophils/ HPF) increased the likelihood of fully active EoE in the next 2 years, as indicated by the 4.4-fold odds ratio between EDP-positive and EDP-negative histologically ambiguous patients, demonstrating a potential predictive medicine capacity. Although these data are limited by the nonprospective design, they are consistent with the recent finding that long-term consequences of esophageal eosinophilia emerge at eosinophil levels >5 eosinophils/ HPF 20 and with another study showing that 36% of the "low-grade esophageal eosinophilia"cases (1À14 eosinophils/HPF) are truly EoE, as proved by subsequent repetitive endoscopy. 19 An EDP analysis of 177 patient samples (132 fresh and 45 FFPE) achieved the historically high approximately 98% specificity and approximately 96% sensitivity using the EoE score (SDCT) algorithm. Notably, it is likely that the diagnostic merit of EDP is underestimated because the caveat for this study is using the histological method as the "gold standard."As mentioned previously, the 15 eosinophil cut-off itself is debatable due to the heterogeneity of eosinophilia, the variability of counting, and shared eosinophilia with non-EoE diseases. On the other hand, although the EDP demonstrated unprecedented performance using samples from our institution and was able to perform well with fresh and FFPE samples from other sites in multi-centered studies (data not shown), an external validation will be helpful to strengthen the EDP application. With high diagnostic merit, a value for personalized medicine, and ability to distinguish EoE remission tissue from healthy tissue, the EDP represents the next generation for EoE diagnosis. Although histological diagnosis by eosinophil count and an empirical eosinophilia cut-off will still prove to be useful under certain circumstances, the EDP offers an accurate, rapid, informative, and low-cost diagnosis based on the EoE transcriptome as a biomarker for evaluating therapeutic interventions. Our results provide proof-of-principle for the application of tissue-based molecular diagnosis of inflammatory diseases, especially for esophagitis and a growing number of other eosinophil-associated inflammatory diseases, such as asthma.
